Bluebird Lays Some New Eggs, But They'll Take Time To Hatch

Management outlined four new oncology and one rare disease program during an analyst day. CEO Nick Leschly also talked to Scrip about staying focused on R&D as other gene therapy players get bought out.

Eastern bluebird eggs in a nest on a blue background - Image

While bluebird bio Inc. is gearing up to launch its first commercial drug – the gene therapy Zynteglo for transfusion-dependent beta-thalassemia (TDT) – shortly in Europe, the company is building out its pipeline with a focus on immuno-oncology and rare diseases.

Bluebird held an analyst day in New York City on 9 May to highlight commercial plans for Zynteglo (previously LentiGlobin)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Gene Therapies

More from Advanced Therapies